Aldeyra Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Aldeyra Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.60. The average 1-year stock price forecast is 385.29% higher than the current stock price, while the lowest is $2.00 (+47.06%) and the highest is $13 (+855.88%).

Price Target: $6.60 (+385.29%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$2.00	$6.60	$5.00	$13
Change	+47.06%	+385.29%	+267.65%	+855.88%

* Price targets were last updated on Aug 17, 2026.

Analyst Ratings

The average analyst rating for Aldeyra Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Jan '26	Mar '26	Apr '26	May '26	Jul '26	Aug '26
Strong Buy	5	4	3	3	4	4
Buy	1	1	1	1	1	1
Hold	0	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	5	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Hold Reiterates $2	Hold	Reiterates	$2	+47.06%	Aug 17, 2026

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

6.72M

EPS This Year

-0.34

from -0.56

EPS Next Year

-0.28

from -0.34

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-56.22M	-62.68M	-42.79M	-60.12M	-35.27M	-21.07M
Net Income	-57.78M	-62.02M	-37.54M	-55.85M	-33.85M	-20.47M
EPS	-	-	-	-	-0.56	-0.34
Free Cash Flow	-	-	-	-	-21.46M	-25.13M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.31
Avg	-0.34
Low	-0.39

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-